Researchers at the University of Maryland School of Medicine developed a new nanoparticle drug formulation that targets a specific receptor on cancer cells and appears to be more effective than a standard nanoparticle therapy currently on the market to treat metastatic breast cancer.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe